查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1324371

2030 年炎症性肠病治疗市场预测 - 按类型、药物类别、给药途径、分销渠道和地区进行的全球分析

Inflammatory Bowel Disease Treatment Market Forecasts to 2030 - Global Analysis By Type (Ulcerative Colitis and Crohn's Disease), Drug Class, Route of Administration, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3个工作天内

价格

据Stratistics MRC预测，2023年全球炎症性肠病治疗市场规模将达到214.7亿美元，预计在预测期内将以5.6%的年复合成长率增长，到2030年达到314.4亿美元。

术语炎症性肠病（IBD）是指溃疡性大肠炎和克罗恩病，这两种胃肠道慢性炎症的疾病。消化器官系统因炎症而遭受长期损害。治疗大肠激躁症的目标是减少引起症状和体征的炎症。在最好的情况下，它可以缓解症状、长期缓解并降低合併的风险。 IBD 的治疗通常涉及药物治疗或手术。

据 ClinicalTrials.gov. 称，在 2,784 项与 IBD 相关的临床试验（包括药物开发、观察性研究等）中，目前仅在美国就进行了 965 项。

市场动态：

患病率上升意味着更多患者接受治疗

许多要素导致溃疡性大肠炎和克罗恩病的患病率不断增加，包括遗传倾向、环境触发因素和免疫系统疾病。大多数罹患溃疡性大肠炎或克罗恩病患者都有家族病史。许多政府机构正在通过教育公众了解这些疾病的症状、诊断和治疗来提高公众对这些疾病的认识。因此，新兴国家消费者对各种治疗的认识不断提高，疾病诊断率不断提高，预计将推动市场扩张。

高成本

在开发中国家，由于缺乏对炎症性肠病的了解，导致接受治疗的人数减少。此外，高昂的治疗成本，包括药物和其他成本，预计将限制炎症性肠病治疗在患者中的使用。此外，生物製剂越来越多地用于治疗溃疡性大肠炎和克罗恩病，但生物製剂治疗的高成本限制了市场的扩张。

由于强大的管道分子组合，产品推出量增加

推动炎症性肠病治疗市场增长的要素包括克罗恩病和溃疡性大肠炎患病率的上升以及全球范围内认识的提高。因此，许多重要的行业公司正在专注于研发，以探索新的有前景的 IBD 治疗候选药物。

新药研发有限和技术挑战

正在开发的治疗 IBD 的新药数量很少，而且大多数都专注于类似的作用机制。因此，製药行业将很难区分其药品，这可能导致价格上涨。 IBD市场涉及许多法律，包括有关临床试验、附加檔和安全监测的法律。对于製药公司来说，遵守这些法规既耗时又昂贵。

COVID-19 的影响：

由于COVID-19的影响，炎症性肠病治疗市场在预测期内扩张更为缓慢。世界各地诊断设施的关闭、旅行限制和封锁是导致这种疾病治疗速度缓慢的一些因素。 2020年产生的收入明显低于2019年。

克罗恩病预计将在预测期内成为最大的部分

在预测期内，克罗恩病预计将占最大份额。克罗恩病患罹患率的上升以及国际上接受克罗恩病治疗的人数都被认为推动了该市场的扩张。例如，据 Deutsches Arztblatt 报导，德国每 10 万人中有 100 至 200 名克罗恩病患者。

预计注射剂领域在预测期内的年复合成长率最高。

由于生物製剂产品核可的增加以及生物製剂在溃疡性大肠炎和克罗恩病治疗中的使用增加，预计注射剂领域在预测期内将表现出最高的年复合成长率。例如，艾伯维 (AbbVie) 于 2021 年 2 月宣布 FDA 批准修美乐 (Humira) 用于治疗年轻患者中度至重度活动性溃疡性大肠炎。 Humira 通过皮下注射给药。因此，用于治疗 IBD 的生物製剂的需求不断增长，支持了注射剂行业的扩张。

占比最高的地区

北美在全球炎症性肠病治疗市场的主导地位是由于存在大量强大的市场参与者及其众多的战略倡议。此外，该地区改进的报销做法、更高的治疗率以及增加创新疗法的处方正在支持该地区的扩张。持续努力发现创新疗法和政府支持措施预计也将推动该地区的扩张。

复合年复合成长率最高的地区：

预计亚太地区将在预测期内实现最高增长。未来几年推动市场扩张的关键原因包括人口高龄化、炎症性疾病市场发展的巨大潜力、炎症性肠病患病率的增加以及该地区健康状况的改善，例如护理政策。此外，该地区主要企业的投资增加以及生物仿製药和生物製剂的接受度不断提高，预计将在不久的将来支持市场扩张。

免费定制服务：

订阅此报告的客户将收到以下免费定制选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和年复合成长率（注：基于可行性检查）
  • 竞争标杆管理
    • 根据产品系列、地域分布和战略联盟对主要企业进行基准测试

目录

第1章执行摘要

第2章前言

  • 执行摘要
  • 利益相关者
  • 调查范围
  • 调查方法
    • 资料挖掘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第3章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 新兴市场
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球炎症性肠病治疗市场：按类型

  • 溃疡性大肠炎
  • 克罗恩病

第6章全球炎症性肠病治疗市场：按药物类别

  • JAK抑製剂
  • 抗整合素药物
  • IL抑製剂
  • 肿瘤坏死因子抑製剂
  • 皮质类固醇
  • 氨基水杨酸盐
  • 按其他药物类别

第7章炎症性肠病治疗的全球市场：按给药途径

  • 注射
  • 口服剂

第8章全球炎症性肠病治疗市场：按分销渠道划分

  • 网上药房
  • 零售药房
  • 医院药房

第9章全球炎症性肠病治疗市场：按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第10章进展

  • 合同、伙伴关係、联盟和合资企业
  • 收购和合併
  • 新产品上市
  • 业务扩展
  • 其他关键策略

第11章公司简介

  • Allergan plc.
  • Janssen Biotech
  • Celltrion Inc.
  • Pfizer Inc
  • Merck & co., inc
  • Bristol-myers squibb company
  • Bausch health companies inc
  • Takeda Pharmaceutical Company Limited
  • Novartis AG
  • UCB SA
  • Amgen Inc
  • Johnson & Johnson Services, Inc
  • Biogen
  • AbbVie Inc.,
Product Code: SMRC23596

According to Stratistics MRC, the Global Inflammatory Bowel Disease Treatment Market is accounted for $21.47 billion in 2023 and is expected to reach $31.44 billion by 2030 growing at a CAGR of 5.6% during the forecast period. The term "inflammatory bowel disease" (IBD) is used to describe ulcerative colitis and Crohn's disease, two conditions in which the GI tract is chronically inflamed. The digestive system becomes damaged over time by inflammation. The goal of treating irritable bowel syndrome is to reduce the inflammation that is the source of your signs and symptoms. In the best-case scenario, this might lead to symptom relief, a long-term remission, and lowered complications risks. For the treatment of IBD, drugs or surgery are usually employed.

According to ClinicalTrials.gov., there are currently 965 clinical trials being undertaken in the United States alone out of the 2,784 clinical trials (including medication development, observational studies, and others) connected to IBD.

Market Dynamics:

Driver:

Increasing prevalence of disease is presenting a large patient pool undergoing treatment

Many factors, including genetic predisposition, environmental triggers, and immune system disturbances, are responsible for the rising prevalence of ulcerative colitis and Crohn's disease. The majority of individuals who have ulcerative colitis or Crohn's disease have a family history of the condition. By educating the public about these diseases' symptoms, diagnoses, and treatments, a number of government agencies are raising public awareness of these illnesses. Therefore, it is projected that growing consumer awareness of various treatment alternatives and rising disease diagnosis rates in developing nations will boost market expansion.

Restraint:

High cost

In underdeveloped nations, there is a lack of knowledge regarding inflammatory bowel disease, which lowers the number of individuals receiving treatment. Additionally, it is anticipated that high treatment costs, including those associated with drugs and other expenses, may restrict the use of an inflammatory bowel disease treatment among patients. Additionally, biologics are being used more frequently to treat ulcerative colitis and Crohn's disease, but the market expansion is being constrained by the high costs of biologic treatment.

Opportunity:

Strong portfolio of pipeline molecules to increase product launches

Some of the reasons driving the growth of the inflammatory bowel disease treatment market include the rising prevalence of Crohn's disease and ulcerative colitis, as well as increased awareness of the condition on a global scale. As a result, a number of important industry firms are concentrating on R&D and looking into new prospective candidates for the treatment of IBD.

Threat:

Limited pipeline of new drugs and technical challenges

The number of new medications being developed to treat IBD is rather small, and most of them focus on similar mechanisms of action. The pharmaceutical industry may find it harder to differentiate its medicines as a result, which may put pressure on prices. A number of laws, including those governing clinical trials, labeling, and safety monitoring, pertain to the IBD market. For pharmaceutical companies, complying with these rules can be time- and money-consuming.

COVID-19 Impact:

The market for treating inflammatory bowel disease expanded more slowly during the predicted period as a result of COVID-19's effects. The closure of diagnostic facilities, travel restrictions, and lockdowns in numerous nations worldwide are a few of the causes contributing to the disease's delayed rate of treatment. The revenue generated in 2020 was significantly lower than it was in 2019.

The crohn's disease segment is expected to be the largest during the forecast period

The Crohn's disease segment is expected to hold the largest share during the forecast period. The rising incidence of Crohn's disease and the number of people undergoing treatment for it internationally are both credited with driving the expansion of this market. For instance, according to the Deutsches Arztblatt, there are 100 to 200 cases of Crohn's disease per 100,000 people in Germany.

The injectables segment is expected to have the highest CAGR during the forecast period

Due to rising product approvals for biologics as well as rising biologic usage for the treatment of ulcerative colitis and Crohn's disease, the injectables sector is anticipated to have the highest CAGR over the projection period. For instance, AbbVie Inc. announced in February 2021 that the FDA had approved HUMIRA for the treatment of moderate to severe active ulcerative colitis in juvenile patients. Through subcutaneous injections, HUMIRA is administered. Thus, the expansion of the injectables sector is supported by the rising demand for biologics for the treatment of IBD.

Region with largest share:

North America dominated the global market for the treatment of inflammatory bowel disease as a result of the existence of numerous powerful market players and the numerous strategic initiatives they carried out there. Additionally, the region's improved reimbursement practices, high treatment rates, and rising prescription of innovative treatments are aiding regional expansion. The region's expansion is also predicted to be fueled by continuous efforts to discover innovative therapies and supportive government initiatives.

Region with highest CAGR:

Over the forecast period, Asia-Pacific is expected to experience the highest growth. Some of the key reasons driving market expansion in the upcoming years include an aging population, a high chance of developing inflammatory diseases, an increase in the prevalence of inflammatory bowel diseases, and better healthcare policies in the area. Additionally, increased investments by top players in the region and the increasing acceptance of biosimilars and biologics are anticipated to fuel market expansion in the near future.

Key players in the market:

Some of the key players in Inflammatory Bowel Disease Treatment market include: Allergan plc., Janssen Biotech, Celltrion Inc., Pfizer Inc, Merck & co., inc, Bristol-myers squibb company, Bausch health companies inc, Takeda Pharmaceutical Company Limited, Novartis AG, UCB S.A., Amgen Inc, Johnson & Johnson Services, Inc, Biogen and AbbVie Inc.

Key Developments:

In October 2021, Bristol-Myers Squibb Company announced the approval of Zeposia (ozanimod) by the Committee for Medicinal Products for Human Use (CHMP) for the treatment of adults with moderately to severely active Ulcerative Colitis (UC).

In February 2021, the European Commission (EC) granted marketing authorization to CELLTRION INC.'s Yuflyma biosimilar used to treat adult and pediatric Crohn's disease and ulcerative colitis.

Types Covered:

  • Ulcerative Colitis
  • Crohn's Disease

Drug Class Covered:

  • JAK inhibitors
  • Anti-integrin
  • IL inhibitors
  • TNF inhibitors
  • Corticosteroids
  • Aminosalicylates
  • Other Drug Class

Route of Administrations Covered:

  • Injectable
  • Oral

Distribution Channels Covered:

  • Online Pharmacy
  • Retail Pharmacy
  • Hospital Pharmacy

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Inflammatory Bowel Disease Treatment Market, By Type

  • 5.1 Introduction
  • 5.2 Ulcerative Colitis
  • 5.3 Crohn's Disease

6 Global Inflammatory Bowel Disease Treatment Market, By Drug Class

  • 6.1 Introduction
  • 6.2 JAK inhibitors
  • 6.3 Anti-integrin
  • 6.4 IL inhibitors
  • 6.5 TNF inhibitors
  • 6.6 Corticosteroids
  • 6.7 Aminosalicylates
  • 6.8 Other Drug Class

7 Global Inflammatory Bowel Disease Treatment Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Injectable
  • 7.3 Oral

8 Global Inflammatory Bowel Disease Treatment Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Online Pharmacy
  • 8.3 Retail Pharmacy
  • 8.4 Hospital Pharmacy

9 Global Inflammatory Bowel Disease Treatment Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Allergan plc.
  • 11.2 Janssen Biotech
  • 11.3 Celltrion Inc.
  • 11.4 Pfizer Inc
  • 11.5 Merck & co., inc
  • 11.6 Bristol-myers squibb company
  • 11.7 Bausch health companies inc
  • 11.8 Takeda Pharmaceutical Company Limited
  • 11.9 Novartis AG
  • 11.10 UCB S.A.
  • 11.11 Amgen Inc
  • 11.12 Johnson & Johnson Services, Inc
  • 11.13 Biogen
  • 11.14 AbbVie Inc.,

List of Tables

  • Table 1 Global Inflammatory Bowel Disease Treatment Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Inflammatory Bowel Disease Treatment Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Inflammatory Bowel Disease Treatment Market Outlook, By Ulcerative Colitis (2021-2030) ($MN)
  • Table 4 Global Inflammatory Bowel Disease Treatment Market Outlook, By Crohn's Disease (2021-2030) ($MN)
  • Table 5 Global Inflammatory Bowel Disease Treatment Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 6 Global Inflammatory Bowel Disease Treatment Market Outlook, By JAK inhibitors (2021-2030) ($MN)
  • Table 7 Global Inflammatory Bowel Disease Treatment Market Outlook, By Anti-integrin (2021-2030) ($MN)
  • Table 8 Global Inflammatory Bowel Disease Treatment Market Outlook, By IL inhibitors (2021-2030) ($MN)
  • Table 9 Global Inflammatory Bowel Disease Treatment Market Outlook, By TNF inhibitors (2021-2030) ($MN)
  • Table 10 Global Inflammatory Bowel Disease Treatment Market Outlook, By Corticosteroids (2021-2030) ($MN)
  • Table 11 Global Inflammatory Bowel Disease Treatment Market Outlook, By Aminosalicylates (2021-2030) ($MN)
  • Table 12 Global Inflammatory Bowel Disease Treatment Market Outlook, By Other Drug Class (2021-2030) ($MN)
  • Table 13 Global Inflammatory Bowel Disease Treatment Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 14 Global Inflammatory Bowel Disease Treatment Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 15 Global Inflammatory Bowel Disease Treatment Market Outlook, By Oral (2021-2030) ($MN)
  • Table 16 Global Inflammatory Bowel Disease Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 17 Global Inflammatory Bowel Disease Treatment Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 18 Global Inflammatory Bowel Disease Treatment Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 19 Global Inflammatory Bowel Disease Treatment Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 20 North America Inflammatory Bowel Disease Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 21 North America Inflammatory Bowel Disease Treatment Market Outlook, By Type (2021-2030) ($MN)
  • Table 22 North America Inflammatory Bowel Disease Treatment Market Outlook, By Ulcerative Colitis (2021-2030) ($MN)
  • Table 23 North America Inflammatory Bowel Disease Treatment Market Outlook, By Crohn's Disease (2021-2030) ($MN)
  • Table 24 North America Inflammatory Bowel Disease Treatment Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 25 North America Inflammatory Bowel Disease Treatment Market Outlook, By JAK inhibitors (2021-2030) ($MN)
  • Table 26 North America Inflammatory Bowel Disease Treatment Market Outlook, By Anti-integrin (2021-2030) ($MN)
  • Table 27 North America Inflammatory Bowel Disease Treatment Market Outlook, By IL inhibitors (2021-2030) ($MN)
  • Table 28 North America Inflammatory Bowel Disease Treatment Market Outlook, By TNF inhibitors (2021-2030) ($MN)
  • Table 29 North America Inflammatory Bowel Disease Treatment Market Outlook, By Corticosteroids (2021-2030) ($MN)
  • Table 30 North America Inflammatory Bowel Disease Treatment Market Outlook, By Aminosalicylates (2021-2030) ($MN)
  • Table 31 North America Inflammatory Bowel Disease Treatment Market Outlook, By Other Drug Class (2021-2030) ($MN)
  • Table 32 North America Inflammatory Bowel Disease Treatment Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 33 North America Inflammatory Bowel Disease Treatment Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 34 North America Inflammatory Bowel Disease Treatment Market Outlook, By Oral (2021-2030) ($MN)
  • Table 35 North America Inflammatory Bowel Disease Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 36 North America Inflammatory Bowel Disease Treatment Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 37 North America Inflammatory Bowel Disease Treatment Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 38 North America Inflammatory Bowel Disease Treatment Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 39 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 40 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Type (2021-2030) ($MN)
  • Table 41 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Ulcerative Colitis (2021-2030) ($MN)
  • Table 42 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Crohn's Disease (2021-2030) ($MN)
  • Table 43 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 44 Europe Inflammatory Bowel Disease Treatment Market Outlook, By JAK inhibitors (2021-2030) ($MN)
  • Table 45 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Anti-integrin (2021-2030) ($MN)
  • Table 46 Europe Inflammatory Bowel Disease Treatment Market Outlook, By IL inhibitors (2021-2030) ($MN)
  • Table 47 Europe Inflammatory Bowel Disease Treatment Market Outlook, By TNF inhibitors (2021-2030) ($MN)
  • Table 48 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Corticosteroids (2021-2030) ($MN)
  • Table 49 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Aminosalicylates (2021-2030) ($MN)
  • Table 50 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Other Drug Class (2021-2030) ($MN)
  • Table 51 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 52 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 53 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Oral (2021-2030) ($MN)
  • Table 54 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 55 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 56 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 57 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 58 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 59 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Type (2021-2030) ($MN)
  • Table 60 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Ulcerative Colitis (2021-2030) ($MN)
  • Table 61 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Crohn's Disease (2021-2030) ($MN)
  • Table 62 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 63 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By JAK inhibitors (2021-2030) ($MN)
  • Table 64 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Anti-integrin (2021-2030) ($MN)
  • Table 65 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By IL inhibitors (2021-2030) ($MN)
  • Table 66 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By TNF inhibitors (2021-2030) ($MN)
  • Table 67 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Corticosteroids (2021-2030) ($MN)
  • Table 68 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Aminosalicylates (2021-2030) ($MN)
  • Table 69 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Other Drug Class (2021-2030) ($MN)
  • Table 70 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 71 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 72 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Oral (2021-2030) ($MN)
  • Table 73 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 74 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 75 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 76 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 77 South America Inflammatory Bowel Disease Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 78 South America Inflammatory Bowel Disease Treatment Market Outlook, By Type (2021-2030) ($MN)
  • Table 79 South America Inflammatory Bowel Disease Treatment Market Outlook, By Ulcerative Colitis (2021-2030) ($MN)
  • Table 80 South America Inflammatory Bowel Disease Treatment Market Outlook, By Crohn's Disease (2021-2030) ($MN)
  • Table 81 South America Inflammatory Bowel Disease Treatment Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 82 South America Inflammatory Bowel Disease Treatment Market Outlook, By JAK inhibitors (2021-2030) ($MN)
  • Table 83 South America Inflammatory Bowel Disease Treatment Market Outlook, By Anti-integrin (2021-2030) ($MN)
  • Table 84 South America Inflammatory Bowel Disease Treatment Market Outlook, By IL inhibitors (2021-2030) ($MN)
  • Table 85 South America Inflammatory Bowel Disease Treatment Market Outlook, By TNF inhibitors (2021-2030) ($MN)
  • Table 86 South America Inflammatory Bowel Disease Treatment Market Outlook, By Corticosteroids (2021-2030) ($MN)
  • Table 87 South America Inflammatory Bowel Disease Treatment Market Outlook, By Aminosalicylates (2021-2030) ($MN)
  • Table 88 South America Inflammatory Bowel Disease Treatment Market Outlook, By Other Drug Class (2021-2030) ($MN)
  • Table 89 South America Inflammatory Bowel Disease Treatment Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 90 South America Inflammatory Bowel Disease Treatment Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 91 South America Inflammatory Bowel Disease Treatment Market Outlook, By Oral (2021-2030) ($MN)
  • Table 92 South America Inflammatory Bowel Disease Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 93 South America Inflammatory Bowel Disease Treatment Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 94 South America Inflammatory Bowel Disease Treatment Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 95 South America Inflammatory Bowel Disease Treatment Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 96 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 97 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Type (2021-2030) ($MN)
  • Table 98 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Ulcerative Colitis (2021-2030) ($MN)
  • Table 99 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Crohn's Disease (2021-2030) ($MN)
  • Table 100 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 101 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By JAK inhibitors (2021-2030) ($MN)
  • Table 102 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Anti-integrin (2021-2030) ($MN)
  • Table 103 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By IL inhibitors (2021-2030) ($MN)
  • Table 104 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By TNF inhibitors (2021-2030) ($MN)
  • Table 105 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Corticosteroids (2021-2030) ($MN)
  • Table 106 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Aminosalicylates (2021-2030) ($MN)
  • Table 107 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Other Drug Class (2021-2030) ($MN)
  • Table 108 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 109 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 110 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Oral (2021-2030) ($MN)
  • Table 111 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 112 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 113 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 114 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)